Marksans Pharma Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mw7tbk00190j9hir21fub55y.pdf

Key Takeaways


Teva Facility Ramp-Up

Mark Saldanha: "Today, not in the last quarter, not in the fourth quarter, but in the first quarter, we are trending around at Rs. 400 crores, which is pretty much half of what we had spoken of Rs. 800 crores coming out of the plant."

U.S. Market & Tariff Exposure

Mark Saldanha: "If it is extremely negligible and insignificant, we may not bother burdening anything, probably try to get the cost of goods down to nullify it. But most likely, if it is 10% or anything above 10%, we will definitely work on passing it down."

Margins & Cost Structure

Mark Saldanha: "I do believe we will maintain our EBITDA, our historic EBITDA that we have done but improve on that."

Product Pipeline & Commercialization


Geographic & M&A Strategy

Mark Saldanha: "In pharma, you have got to invest today to see returns after 2 years. So technically, we are always on the lookout for facility expansion."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue target₹3,000 crores revenue (from ₹2,600 crores in FY25)FY26
Corporate growth rate17.5% to 18% year-on-year topline growthFY26 and aiming for next 3 years
U.S. growth rate25% plus year-on-yearFY26 and next couple of years
Teva plant utilizationHit 50% of 800 crore unit capacityWithin next 6 months
Teva plant full rampRamp to 800 crore unitsLatter half of FY26 or early next year
Teva plant revenueMinimum ₹500-odd crores, trending toward ₹600-700 croresLatter part of FY26
EBITDA marginMaintain historic levels and improve; 21-22% once operating leverage materializesFY26 and as Teva utilization rises
R&D expenditure1.9% to 2.0% of revenueYear-on-year basis
CAPEX$8 million to $10 million overallFY26
Freight costReturn to 4% of salesFY26
Working capital125 to 135 daysOngoing
Product launches~70 products across cold, digestive, pain, prescription segmentsBetween now and September
Order book execution$22 crore order book shipped in trending pattern starting SeptemberFY26
Order book target$300 million statusWithin next 2 years
Tariff pass-throughPass down to customers if 10% or aboveIf and when implemented

Key Metrics

MetricQ4 FY25
Operating revenue₹708.5 cr, +26.5% YoY
U.S. and North America revenue₹328.6 cr, +34.1% YoY
U.K. and EU formulation revenue₹274.1 cr, +17.7% YoY
Australia and New Zealand revenue₹76.5 cr, +20.9% YoY
Rest of world revenue₹29.3 cr, +55% YoY
Gross margin54.1%, +228 bps YoY
EBITDA₹125.8 cr, +14.7% YoY
EBITDA margin17.8%, -183 bps YoY
Profit after tax₹90.7 cr, +16.9% YoY
EPS₹2
R&D spend₹23.47 cr, up from ₹11.71 cr in Q3 FY25
Teva facility volumes~20 crore units, trending at ~35 crore tablets in early FY26
Other facilities capacity utilization~65%
Working capital cycle127 days
Order book$22 crore (₹220 cr), targeting $300 million within 2 years
Freight cost as a percentage of sales5% in FY25, expected to return to 4% in FY26